Pumitamig

Pumitamig 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Locally Advanced Non-Small Cell Lung Cancer (NSCLC)、Metastatic Non-Small Cell Lung Cancer (NSCLC)、Breast Neoplasms、Lung Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Pumitamig 研究

• A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  II 期招募中美国Argentina澳大利亚BrazilNCT07680764

• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

  I 期 / II 期招募中美国澳大利亚加拿大德国NCT04895709

• ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  III 期招募中美国Argentina澳大利亚比利时NCT07173751

• A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  I 期 / II 期招募中美国澳大利亚比利时中国NCT07070232

• A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

  I 期 / II 期招募中美国Argentina澳大利亚加拿大NCT07293351

• A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

  I 期 / II 期招募中美国澳大利亚中国德国NCT07111520

• Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

  II 期招募中美国澳大利亚South Korea西班牙NCT06841055

• A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  II 期招募中美国比利时加拿大中国NCT07492680

• A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

  I 期 / II 期招募中美国中国意大利日本NCT07325136

• A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

  I 期 / II 期招募中美国德国日本西班牙NCT07079631

• A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

  I 期 / II 期招募中美国澳大利亚比利时中国NCT07843940

• A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

  I 期 / II 期招募中美国澳大利亚加拿大中国NCT06827236

• Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer

  I 期 / II 期招募中美国NCT07579221

• A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

  I 期 / II 期招募中澳大利亚中国NCT07147348

• A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

  II 期招募中中国NCT07297212

• A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

  I 期 / II 期招募中美国中国丹麦日本NCT07160725

• Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  II 期 / III 期招募中美国Argentina澳大利亚比利时NCT06712316

• A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

  I 期 / II 期招募中美国比利时丹麦法国NCT06697197

• PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

  II 期招募中中国NCT07133750

• A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  III 期招募中美国Argentina澳大利亚奥地利NCT07361497

• A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

  I 期 / II 期招募中美国澳大利亚Chile中国NCT07291076

• A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  II 期 / III 期招募中美国Argentina澳大利亚奥地利NCT07221357

• Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

  III 期招募中美国澳大利亚中国法国NCT06712355

• A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

  I 期招募中美国加拿大法国意大利NCT07195682

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。